UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2017
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
This Form 6-K is incorporated by reference into the Registrant’s Registration Statement on Form S-8 (Registration No. 333-214817).
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a notice published by the Registrant entitled “Update on the Announcement on Moving to Exclusive Trading on the NASDAQ.”
| Exhibit | | |
99.1 | | Notice titled “Update on the Announcement on Moving to Exclusive Trading on the NASDAQ” published on June 26, 2017 (Unofficial Translation from Hebrew) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Cellect Biotechnology Ltd. |
| | | |
| Date: June 26, 2017 | By: | /s/ Eyal Leibovitz |
| | | Name: Eyal Leibovitz |
| | | Title: Chief Financial Officer |
